We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ginger-Derived Doxorubicin-Loaded Nanovectors as Drug Delivery for Cancer Therapy

By LabMedica International staff writers
Posted on 20 Sep 2016
A novel type of nanoparticle drug transport system based on lipids isolated from ginger was used to deliver the toxic chemotherapeutic agent doxorubicin (Dox) to colon cancer cells with minimal damage to normal tissues.

Although in use for more than 40 years as a primary chemotherapy drug, Dox is known to cause serious heart problems. To prevent these, doctors may limit the amount of Dox given to each patient so that the total amount a patient receives over her or his entire lifetime is 550 milligrams per square meter, or less. Furthermore, the necessity to stop treatment to protect the patient from heart disease may diminish the usefulness of Dox in treating cancer.

Image: Ginger is the source of a novel class of nanolipid transport vector (Photo courtesy of Georgia State University).
Image: Ginger is the source of a novel class of nanolipid transport vector (Photo courtesy of Georgia State University).

In a new approach to safely deliver Dox to colon tumors, investigators at Georgia State University (Atlanta, USA) created nanoparticles from ginger and reassembled their lipids into ginger-derived nanovectors (GDNVs). These nanovectors were capable of loading Dox with high efficiency and showed a better pH-dependent drug-release profile than commercially available liposomal-Dox. GDNVs were shown to be taken up efficiently by colon cancer cells.

The GDNVs were modified by conjugating them with the targeting ligand folic acid (FA-GDNVs), which directed the Dox-loaded nanovectors specifically to Colon-26 tumors in vivo. Results published in the August 5, 2016, online edition of the journal Molecular Therapy showed treatment with the modified nanovectors enhanced the chemotherapeutic inhibition of tumor growth compared with the free drug.

“Our results show that FA nanovectors made of edible ginger-derived lipids could shift the current paradigm of drug delivery away from artificially synthesized nanoparticles toward the use of nature-derived nanovectors from edible plants,” said senior author Dr. Didier Merlin, professor of biomedical sciences at Georgia State University. “Because they are nontoxic and can be produced on a large scale, FA nanovectors derived from edible plants could represent one of the safest targeted therapeutic delivery platforms.”

Related Links:
Georgia State University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries